Pembrolizumab associated Stevens–Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma

Pembrolizumab is a humanised therapeutic antibody against the PD‐1 receptor. It has been used in various advanced cancer immunotherapies. Here, we report an extremely rare case of a 32‐year‐old man who developed Stevens–Johnson syndrome (SJS) with porokeratosis simultaneously during pembrolizumab tr...

Full description

Saved in:
Bibliographic Details
Published inAustralasian journal of dermatology Vol. 63; no. 1; pp. e71 - e74
Main Authors Zhang, Jing, Zhang, Peng, Xu, Qiu‐Yun, Zhu, Yan‐Ting, Chen, Wen, Ji, Chao
Format Journal Article
LanguageEnglish
Published Australia Wiley Subscription Services, Inc 01.02.2022
Subjects
Adult
Antibodies, Monoclonal, Humanized - adverse effects
Antineoplastic Agents, Immunological - adverse effects
Cancer immunotherapy
Carcinoma, Hepatocellular - drug therapy
Hepatocellular carcinoma
Humans
immune checkpoint inhibitors
Liver cancer
Liver Neoplasms - drug therapy
Male
PD‐1 inhibitor
Pembrolizumab
porokeratosis
Porokeratosis - chemically induced
Skin diseases
Stevens-Johnson Syndrome - etiology
Stevens–Johnson syndrome
toxic epidermal necrolysis
porokeratosis
Stevens-Johnson syndrome
pembrolizumab
PD-1 inhibitor
immune checkpoint inhibitors
toxic epidermal necrolysis
Online AccessGet full text

Cover

More Information
Summary:Pembrolizumab is a humanised therapeutic antibody against the PD‐1 receptor. It has been used in various advanced cancer immunotherapies. Here, we report an extremely rare case of a 32‐year‐old man who developed Stevens–Johnson syndrome (SJS) with porokeratosis simultaneously during pembrolizumab treatment for primary hepatocellular carcinoma (T3N1M1).
Bibliography:Funding: This work was supported by grants from the Natural Science Foundation of Fujian Province (2020J02053) and the Startup Fund for scientific research, Fujian Medical University (2019QH2033).
Jing Zhang, MD. Peng Zhang, MD. Qiu‐Yun Xu, MD. Yan‐Ting Zhu, MD. Wen Chen, MD. Chao Ji, MD, PhD.
Conflict of interest: The authors declare that there is no conflict of interest.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0004-8380
1440-0960
1440-0960
DOI:10.1111/ajd.13704